Lopaserv-P Tablet is a pharmaceutical formulation combining L-Ornithine L-Aspartate (150 mg) and Pancreatin (100 mg), designed to support hepatic function and improve digestive enzyme activity. L-Ornithine L-Aspartate is an amino acid compound that facilitates ammonia detoxification by enhancing the urea cycle, thereby reducing elevated blood ammonia levels commonly observed in hepatic encephalopathy and chronic liver diseases. Pancreatin, a mixture of digestive enzymes including amylase, lipase, and protease, aids in the breakdown of carbohydrates, fats, and proteins, improving nutrient absorption in patients with pancreatic insufficiency or digestive disorders. Lopaserv-P is indicated for adjunctive therapy in the management of hepatic encephalopathy, chronic liver dysfunction, and exocrine pancreatic insufficiency. The combination therapy helps restore metabolic balance by promoting detoxification and enhancing digestion. It is generally well-tolerated when administered as prescribed; however, caution is advised in patients with hypersensitivity to any component. Dosage and duration should be individualized based on clinical response and physician guidance. Lopaserv-P Tablet should be used as part of a comprehensive treatment plan including dietary modifications and monitoring of liver and pancreatic function parameters.